Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

In our comprehensive analyses of 1422 TCS with state-of-the-art audiologic testing, cisplatin showed a highly significant dose-response relationship with hearing loss (p = 0.0004).

also in 132,142 other papers

A paediatric investigation found only a marginally significant (P = 0.050) difference in sodium thiosulfate's protective effect on cisplatin-related ototoxicity for patients with Hispanic ethnicity. 15 There have been, however, a number of pharmacogenomic studies of cisplatin-related hearing loss (reviewed by Hong et al., 17 ) so it is likely that genetic variants more prevalent in certain populations could account in part for our findings.

also in 26,082 other papers